Literature DB >> 12470210

Identifying molecular targets mediating the anticancer activity of histone deacetylase inhibitors: a work in progress.

B G Gabrielli1, R W Johnstone, N A Saunders.   

Abstract

The anticancer properties of histone deacetylase inhibitors have been known for some time. However, it is only recently that the functional identities of the intracellular targets mediating the anticancer properties have started to be revealed. These targets appear to play significant roles in cell cycle control, apoptosis and differentiation. Importantly, the modulation of these activities is likely to be mediated by alterations in the acetylation status of both histone and non-histone targets. Identification of these targets, and the specific histone deacetylase enzymes that modulate them, is an important step in designing rational-based therapies for the treatment of cancer. In this review we discuss the state of progress in identifying the molecular pathways/events mediating the anticancer activity of histone deacetylase inhibitors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12470210     DOI: 10.2174/1568009023333818

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  5 in total

1.  Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim.

Authors:  Yan Zhao; Jing Tan; Li Zhuang; Xia Jiang; Edison T Liu; Qiang Yu
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-21       Impact factor: 11.205

2.  Isoform-specific up-regulation of plasma membrane Ca2+ATPase expression during colon and gastric cancer cell differentiation.

Authors:  Polett Ribiczey; Attila Tordai; Hajnalka Andrikovics; Adelaida G Filoteo; John T Penniston; Jocelyne Enouf; Agnes Enyedi; Béla Papp; Tünde Kovács
Journal:  Cell Calcium       Date:  2007-04-11       Impact factor: 6.817

Review 3.  Nonhistone protein acetylation as cancer therapy targets.

Authors:  Brahma N Singh; Guanghua Zhang; Yi L Hwa; Jinping Li; Sean C Dowdy; Shi-Wen Jiang
Journal:  Expert Rev Anticancer Ther       Date:  2010-06       Impact factor: 4.512

4.  Transcriptional regulation of human osteopontin promoter by histone deacetylase inhibitor, trichostatin A in cervical cancer cells.

Authors:  Priyanka Sharma; Santosh Kumar; Gopal C Kundu
Journal:  Mol Cancer       Date:  2010-07-07       Impact factor: 27.401

5.  Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells.

Authors:  Taofeek K Owonikoko; Suresh S Ramalingam; Beatriz Kanterewicz; Trent E Balius; Chandra P Belani; Pamela A Hershberger
Journal:  Int J Cancer       Date:  2010-02-01       Impact factor: 7.396

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.